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Abstract
Natural T regulatory cells (Tregs) are challenging to expand ex vivo, and this has severely hindered in vivo evaluation of their
therapeutic potential. All trans retinoic acid (ATRA) plays an important role in mediating immune homeostasis in vivo, and
we investigated whether ATRA could be used to promote the ex vivo expansion of Tregs purified from adult human
peripheral blood. We found that ATRA helped maintain FOXP3 expression during the expansion process, but this effect was
transient and serum-dependent. Furthermore, natural Tregs treated with rapamycin, but not with ATRA, suppressed
cytokine production in co-cultured effector T cells. This suppressive activity correlated with the ability of expanded Tregs to
induce FOXP3 expression in non-Treg cell populations. Examination of CD45RA+ and CD45RA2 Treg subsets revealed that
ATRA failed to maintain suppressive activity in either population, but interestingly, Tregs expanded in the presence of both
rapamycin and ATRA displayed more suppressive activity and had a more favorable epigenetic status of the FOXP3 gene
than Tregs expanded in the presence of rapamycin only. We conclude that while the use of ATRA as a single agent to
expand Tregs for human therapy is not warranted, its use in combination with rapamycin may have benefit.
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Introduction
FOXP3-expressing, natural Tregs cells play a crucial role in
maintaining immune homeostasis by attenuating aberrant immune
responses. Humans and mice lacking a functional FOXP3 gene
suffer from massive, multi-organ, usually fatal autoimmunity [39].
Given the central role Tregs play in immune control, it has long
been postulated that adoptive transfer of functional Tregs could be a
potent weapon in the fight against autoimmune disease, graft v. host
disease (GVHD), and transplant rejection [1]. The availability of
inbred mouse strains and an easily identifiable population of
CD4+CD25+ Tregs have enabled numerous proof-of-principle
experiments demonstrating that, in mice, adoptively transferred
natural Tregs can treat type 1 diabetes [44], prevent GVHD
[45,21], and increase the success of organ transplantation [12].
The transition from murine studies to human Phase I Treg
clinical trials has been difficult, largely due to difficulties in
isolating and expanding Tregs in an Good Manufacturing Practice
(GMP) manner (reviewed in Riley et al [38]). An additional, and
perhaps even more important issue, centers on the plasticity of the
Treg phenotype. In the right cytokine milieu, a small percentage of
natural Tregs stop expressing FOXP3 and start expressing
inflammatory agents such as IL-17 and IFN-c [27,51]. In mice,
adoptive transfer of these ex-Tregs led to the rapid onset of type 1
diabetes [53]. This raises the significant safety concern that
expanded Tregs targeted to a specific tissue may do more harm
than good if substantial numbers of them differentiate into
inflammatory/effector cells. Given the seriousness of these issues
regarding the stability and function of ex vivo expanded Tregs,
many investigators have sought culture conditions that promote
the stable expansion of fully functional natural Tregs. These
investigations have focused on identifying costimulatory pathways
and soluble reagents that best enable expansion of functional
human Tregs. For example, we previously showed that CD28
costimulation was absolutely necessary for large-scale expansion of
functional human Tregs [18]. With respect to soluble agents that
favor human Treg expansion, rapamycin has emerged as the agent
of choice to date . Rapamycin-mediated mTOR inhibition blocks
critical T cell effector functions such as migration and cytokine
production, and limits T cell expansion. However, Tregs appear to
function effectively in the presence of rapamycin [6]. Importantly,
FOXP3 expression induces the serine/threonine kinase pim-2 [5],
which permits Tregs to evade many rapamycin-imposed signaling
blocks [17]. Thus, Tregs are endowed with a natural resistance to
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15868
rapamycin, allowing them to preferentially expand in its presence.
Nonetheless, rapamycin has drawbacks. While it provides a
selective advantage for Treg growth, it still impairs overall Treg
expansion [7]. This may necessitate extended ex vivo culture and/
or multiple rounds of T cell activation in order to generate
therapeutic levels of Tregs. Additionally, rapamycin has been
shown to promote memory cell formation [3] which may translate
into long term side effects of persistent memory Tregs in some
adoptive Treg cell therapy applications. These drawbacks have
provided the rationale to search for agents that will equal or better
rapamycin in terms of generating pure expanded Treg popula-
tions, while eliminating the rapamycin-imposed decrease in overall
Treg expansion.
Retinoic acid, a derivative of vitamin A, plays an important role
in T cell function and trafficking and has been postulated as an
alternative to rapamycin to promote the expansion of Tregs.
ATRA produced by DCs facilitates de novo generation of FoxP3+
T regulatory cells from CD252 T cell populations in mice [13,43].
Two non-mutually exclusive mechanisms have been proposed to
account for the ATRA-promoted induction of suppressive T cells.
One set of data indicates that ATRA augments TGF-b mediated
signaling [8,50], while other investigators report that ATRA
suppresses the ability of memory T cells to block the induction of
FoxP3 expressing regulatory T cells [19]. Many studies have tried
to mimic the in vivo conversation of Teffs to Tregs by ATRA in vitro
as means to rapidly generate suppressive T cells [33,40,15]. These
induced (i)Tregs are attractive immunotherapeutic agents because
of their ease of generation and their potent function in murine
models of autoimmunity, but questions remain regarding their
stability [10]. Two studies have reported that human
CD4+CD252 T cells derived from adult peripheral and cord
blood were converted to suppressive cells in the presence of TGF-b
and ATRA [24,48]. One of these groups also performed a series of
experiments examining how ATRA affected the expansion and
function of natural Tregs and concluded that ATRA augmented
their suppressive activity and should therefore be considered for
use in Treg-based therapy.
Our studies, in which we amplified natural Tregs ex vivo in the
presence of ATRA, came to different conclusions. We found that
while ATRA did promote FOXP3 expression and suppressive
activity, the effects were transient. Our studies evaluating the
stability of ATRA-cultured human Tregs indicate that ATRA has
no long-term beneficial effect as a single agent and may actually be
detrimental to generating Tregs with durable activity. Further-
more, our studies further highlight that criteria other than in vitro
suppression and FOXP3 expression are required to demonstrate
Treg function and stability. To this end, we provide further data
supporting the analysis of the methylation status of the Treg-
specific demethylated region (TSDR) within the non coding region
of FOXP3 following extended in vitro culture as an indicator of Treg
function and stability. Lastly, the addition of ATRA to rapamycin-
treated cultures improved FOXP3 expression, resulted in less
methylation at the FOXP3 TSDR region, and improved Treg
suppressive activity. These observations suggest that ATRA may
have utility in ex vivo expansion of human Tregs, not as a single
agent, but in combination with rapamycin.
Results
ATRA does not impair human T cell proliferation and
augments FOXP3 expression during ex vivo expansion
The greatest drawback to using rapamycin to culture and
expand Tregs is that the overall Treg yield is disappointing. Before
investigating ATRA-specific effects on Tregs, we determined
whether ATRA affected overall Treg expansion. Based on
previous work [2,30] and our own preliminary experiments, we
found that ATRA exerted effects over a wide concentration range
(10nM–1mM). For our initial studies we added 1 mM ATRA or our
previously defined optimal concentration of rapamycin (100nM) to
purified CD4+, CD25+, CD127dim Tregs, activated them using
KT64.86 cells loaded with anti-CD3 Abs, and monitored cell
expansion for 15 days. As previously described , we observed less T
cell expansion in cultures containing rapamycin (Fig 1A).
Decreased Treg yields were not observed when human Tregs
were expanded in the presence of ATRA, supporting the notion
that ATRA could overcome the major drawback of using
rapamycin to promote ex vivo Treg expansion. It should be noted
that Tregs expanded in the presence of both RAPA and ATRA
grew similarly to cells cultured in the presence of RAPA alone,
indicating that the anti-proliferative effects of RAPA were not
overcome by ATRA (data not shown).
We next examined FOXP3 expression in the expanded T cell
populations (Fig 1B). Overall, the addition of either ATRA or
RAPA appeared to slightly augment FOXP3 expression in
expanded Treg cells (Fig 1C), although this difference did not
reach statistical significance (P = .123 ANOVA for all groups;
P = .08 comparing control and ATRA treated Treg populations).
Notably, purified Tregs from one donor (donor 2) failed to
maintain FOXP3 expression through the two week expansion
period. However, when these same cells were expanded in the
presence of ATRA or RAPA, they maintained high levels of
FOXP3, suggesting that both RAPA and ATRA could help
maintain the Treg phenotype during ex vivo expansion (Fig 1C).
These studies suggest that ATRA, like RAPA, enforces a Treg
phenotype during ex vivo expansion.
Tregs undergoing more than one round of ex vivo
expansion in the presence of ATRA do not maintain their
suppressive activity
Next, we tested the ability of the ATRA-expanded Tregs to
function as suppressive cells. After 10–12 days of culture, the
expanded Treg populations were mixed at varying ratios with
CFSE-labeled autologous PBMCs and anti-CD3 Ab coated beads.
After 4–5 days of co-culture, the ability of expanded Tregs to limit
expansion of the CFSE labeled CD8 T cells was measured by flow
cytometry (Fig 2A). Control Tregs expanded in the absence of
RAPA and ATRA displayed highly variable suppressive activity,
whereas those expanded in the presence of ATRA or RAPA
uniformly maintained high suppressive activity (Fig 2B). Previously,
we demonstrated that Tregs expanded in the presence of rapamycin
could be restimulated using aAPCs coated with anti-CD3/28 Abs
and cultured for an additional 10–12 days without losing their
ability to function in vitro and in vivo. These additional restimulations
may be necessary in scenarios in which there is only limited amount
of starting Tregs (cord blood) or when multiple infusions of Tregs
will be necessary to observe a therapeutic effect. We restimulated
ATRA-expanded Tregs with anti-CD3 Ab-loaded K.64.86 cells to
determine whether ATRA-expanded Tregs could also maintain
their suppressive phenotype after an additional round of expansion
in the presence of ATRA. Restimulated Tregs cultured in the
absence of either RAPA or ATRA had few FOXP3+ cells
remaining after 24–28 days of culture. This decrease could be
attributed to outgrowth of contaminating effectors and/or the
plasticity of the Treg phenotype in the absence of selective agents. In
contrast, Tregs cultured with either RAPA or ATRA maintained
high levels of FOXP3 expression following restimulation (Fig 2C).
However, unlike what was observed with rapamycin-treated Tregs,
2 of 3 ATRA-treated Treg cultures completely lost their suppressive
Influence of ATRA on Natural Tregs
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activity after a single round of restimulation and culture, while
RAPA-treated Tregs robustly suppressed effector cell division in all
cultures (Fig 2D, and data not shown). These data indicate that
ATRA does not promote the expansion of cells with a durable Treg
phenotype, and furthermore, these data emphasize the difficulties of
using FOXP3 expression as the sole surrogate for Treg activity.
Treg expansion performed in the absence of serum
results in more durable Treg suppressive activity
We were interested in understanding how ATRA could induce
a transient but not a sustained Treg phenotype. Several groups
have reported that ATRA requires TGF-b to augment FOXP3
Figure 1. ATRA does not impair human T cell proliferation and augments FOXP3 expression during ex vivo expansion. A. 200,000
sorted primary human Tregs were stimulated with anti-CD3 Ab loaded K.64.86 cells and cultured in the presence of 10% human serum alone for 15
days (control) or in serum-containing medium with the addition of 100 ng/ml of rapamycin (RAPA) or 10 mM ATRA. Cell counts were performed on
Days 5, 8, 12 and 15 and data reflect the average of 3 independent experiments. The error bars reflect standard deviation. B. After 15 days of culture,
each cell population from a single donor described in Panel A was analyzed for CD25 and FOXP3 expression by flow cytometry. C. Composite FOXP3
expression data from 6 independent experiments performed using 6 unique donors. The donor shown in Panel B is donor #4.
doi:10.1371/journal.pone.0015868.g001
Influence of ATRA on Natural Tregs
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expression [32]. The role of TGF-b in promoting Treg
differentiation differs significantly between human and murine
Tregs. TGF-b is necessary and sufficient to convert naı¨ve murine
CD4 T cells into suppressive T cells, while TGF-b induces FOXP3
expression, but not suppressive activity, in naı¨ve human CD4T
cells [46]. Thus, we suspected that TGF-b present in the human
serum used in Treg culture medium may have contributed to the
transient suppressive Treg phenotype observed in Tregs expanded
in ATRA. To test this, we expanded Tregs in the absence of
human serum. We found it necessary to repeat ATRA and RAPA
dose titrations to determine their optimal concentrations in serum-
free medium formulations. ATRA concentrations above 10 ng/ml
were highly toxic to human Tregs cultured in serum-free
conditions (data not shown), whereas the optimal RAPA
concentration remained at 100ng/ml. Thus, ATRA toxicity, but
not RAPA toxicity, is altered by the presence of human serum.
Next, Tregs isolated from three consecutive healthy donors were
cultured for one stimulation cycle only under serum-free
conditions in the presence of ATRA or RAPA. Remarkably,
control Treg cultures expanded similarly under both serum-free
and serum-containing conditions (compare Fig 1A with Fig 3A).
Additionally, we observed that RAPA inhibited Treg expansion,
but ATRA did not, in agreement with our results obtained using
human serum-containing culture medium. FOXP3 levels were
virtually identical between control and ATRA-treated cultures
grown in the absence of serum, whereas RAPA-treated cultures
had higher levels of FOXP3 expression than controls or ATRA-
treated Tregs when grown in the absence of serum (Fig 3B,
P = 0.01 One-Way ANOVA). Finally, ATRA-treated Tregs grown
in the absence of serum exhibited poor suppressive activity
compared to Tregs grown in RAPA (Fig 3C). Thus, these studies
suggest that ex vivo expansion of Tregs should be performed in the
Figure 2. Tregs undergoing more than one round of ex vivo expansion in the presence of ATRA do not maintain their suppressive
activity. A. Highly enriched Tregs expanded for 12–15 days under control conditions, or in the presence of ATRA or RAPA as described in Fig 1, were
tested in a suppression assay. Autologous PBMCs were labeled with CFSE, stimulated using anti-CD3 Ab coated beads, and mixed with either no
Tregs (top panel) or expanded Tregs at Treg:PBMC ratios of 1:2, 1:4 or 1:8. Histograms show the expansion of CD8+ T cells. PBMCs that did not receive
anti-CD3 Ab coated beads were used a negative control. B. Suppressive activity of cultured Tregs from 4 different donors was calculated as described
in the Method and Materials Section. Depicted are the % suppression values obtained from the 1:4 Treg:Eff cultures. C. and D. After a single round of
expansion, Tregs were restimulated using anti-CD3 loaded K.64.86 cells and cultured under the same conditions as during the first stimulation. After
an additional 12 days of culture, FOXP3 expression was analyzed by flow cytometry (C.), and a suppressive assay was performed and analyzed as
described above (D.). FOXP3 data is representative of 3 donors, and the suppressive assay data is representative of 2 of 3 cultures. One donor
maintained suppressive activity in the presence of ATRA treatment (data not shown).
doi:10.1371/journal.pone.0015868.g002
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absence of serum since under certain circumstances, serum
promotes the expansion of T cells that have transient Treg
phenotype and function.
Tregs expanded in the presence of RAPA, but not ATRA,
can induce infectious tolerance
Infectious tolerance refers to the ability of one cell population to
induce a suppressive phenotype in another cell population [35]. As
mentioned earlier, it is currently not possible to obtain a 100%
pure population of FOXP3-expressing cells. Thus, in every
expanded Treg culture, there is a population of non-FOXP3
expressing Teffs. We wished to determine whether Tregs cultured
with ATRA and/or RAPA were capable of inducing infectious
tolerance in non-FOXP3-expressing T cells. Our first set of
experiments involved examination of expanded enriched Treg
populations that contain a mixture of CD4+ FOXP3-negative
Teffs and Tregs that had been expanded with either ATRA and/
or RAPA. We treated the expanded co-cultures with PMA and
ionomycin and examined intracellular IL-2 production to
determine whether expanded Tregs could prevent effector
cytokine production by the FOXP3 non-expressing Teff cells. As
expected, the FOXP3-expressing cells were unable to produce IL-
2 regardless of the culture conditions (Fig 4A). However, in the co-
cultures containing untreated or ATRA-treated Tregs, a signifi-
cant fraction of the FOXP3-negative CD4 T cells produced IL-2
after PMA+ ionomycin treatment. In co-cultures containing Tregs
expanded with RAPA or RAPA plus ATRA, PMA+ ionomycin
stimulation did not result in IL-2 production by the non-FOXP3
expressing cells, supporting the notion that RAPA-expanded Tregs
can induce infectious tolerance.
These data suggested that RAPA2 and ATRA-treated Tregs
differed in their ability to induce infectious tolerance in Teffs, but
other explanations, including the effects of the drugs themselves,
could not be ruled out. To explore this differential induction of
infectious tolerance in greater detail, we asked if ATRA2 or
RAPA-treated expanded Tregs could induce FOXP3 expression
in Teffs. To do this, we mixed anti-CD3 Ab coated, bead
activated, CFSE-labeled CD4 Teff cells with Tregs that had been
activated with anti-CD3 Ab coated K.64.86 aAPCs and cultured
for two days either alone (control) or in the presence of RAPA
and/or ATRA. The Treg populations were extensively washed
prior to mixing with the CD4 T cells to prevent transfer of ATRA
or RAPA, or any other soluble suppressive agent. After three days
of co-culture, we examined whether the unlabeled activated Tregs
could induce FOXP3 expression in the CFSE labeled effector T
cells (Fig 4B). Only Tregs expanded with RAPA or with RAPA
and ATRA were able to induce a suppressor phenotype, as
measured by a ,2-fold increase in the percentage of CFSE-
labeled T cells that expressed FOXP3.
Previous reports indicate that the TGF-b propeptide latency-
associated peptide (LAP) is involved in mediating infectious
tolerance, although alternate mechanisms have been proposed
[34,52]. In order to determine whether LAP expression
correlated with the ability of differentially stimulated Tregs to
induce infectious tolerance, we analyzed LAP expression by
flow cytometry (Figs 4C and 4D). We observed that Tregs
cultured in the presence of RAPA expressed high levels of LAP
relative to Tregs cultured under control conditions, while in
Tregs expanded in the presence of ATRA, cell surface
expression of LAP dropped dramatically. Tregs co-cultured in
both ATRA and RAPA expressed intermediate levels of LAP.
However, Tregs from these combined RAPA/ATRA co-
cultures effectively induced FOXP3 expression in Teff cells
(Fig 4A), suggesting that either other factors expressed by
Figure 3. Treg expansion performed in the absence of serum results in more durable Treg suppressive activity. A. Enriched Tregs were
expanded in the absence of human serum. Where indicated, 10 nM ATRA or 100 ng/ml RAPA were added to the medium and this concentration of
drug was added to media used to feed the cultures. Cell counting was performed on the indicated days. The data reflects the average of 3 cultures
using enriched Tregs from different healthy donors. Error bars represent the standard deviation. (B.) At the end of culture, FOXP3 expression was
measured by flow cytometry, and (C.) an in vitro suppressive assay was performed. For parts B. and C., each symbol refers to data collected from a
single donor.
doi:10.1371/journal.pone.0015868.g003
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RAPA-treated Tregs may contribute to the induction of
infectious tolerance, or the reduced amount of LAP present
on the ATRA/RAPA Tregs was sufficient to induce infectious
tolerance. Together, our data indicates that RAPA expanded
Tregs are better equipped to promote infectious tolerance than
ATRA-expanded Tregs.
Figure 4. Tregs expanded with RAPA, but not ATRA, induce infectious tolerance. A. Enriched Tregs were expanded in the presence of the
indicated compounds. At the end of the culture period (Day 15), the cells were stimulated with PMA+ ionomycin for 4 hrs and intracellular IL-2 and
FOXP3 expression were analyzed by flow cytometry. B. CFSE labeled FOXP3-negative CD4 T cells were activated with anti-CD3 Ab coated beads and
mixed 1:1 with 2 day activated Tregs cultured with the indicated compounds. After 3 days of co-culture, cells were analyzed for FOXP3 expression by
flow cytometry; the CFSE labeled cells are displayed. C. and D. Enriched Tregs were activated and expanded using the indicated culture conditions
and expression of the Latency Associated Peptide (LAP) was determined after 4 days of culture by flow cytometry from a representative single donor
(C.). The composite data from multiple (3) donors is portrayed in D.
doi:10.1371/journal.pone.0015868.g004
Influence of ATRA on Natural Tregs
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ATRA and RAPA affect Treg subsets equally
Since Tregs are a heterogeneous population that can be
subdivided by a variety of cell surface markers, including ICOS,
CD45RA and CD103 [20,23,29,31], we wanted to know if ATRA
was effective in promoting Treg activity in particular subsets but
not others, and if the ability of ATRA to promote Treg expansion
correlated with the relative abundance of a particular Treg subset.
We used CD45RA expression to define Tregs with stable
(CD45RA+) and unstable (CD45RA2) phenotypes . Sort-purified
populations of CD45RA+ and CD45RA2 Tregs were activated
and cultured in the presence of RAPA, ATRA, RAPA+ATRA, or
no additives (control). We observed that compared to the
expanded CD45RA2 subset, all expanded CD45RA+ populations
contained higher percentages of FOXP3-positive cells and also
demonstrated higher suppressor activity overall (Fig 5A–E).
However, in one donor, Treg suppressive activity in the CD45RA+
population was lost after expansion. Suppressive activity could be
restored when these cells were cultured in the presence of RAPA
and RAPA+ATRA, but not ATRA alone. We observed a similar
trend in the experiments using CD45RA2 Tregs. Importantly,
when ATRA was used as a single agent, the suppressive activity of
natural Tregs was diminished in all cultures tested, suggesting that
ATRA could have a detrimental effect on natural Treg function
after ex vivo expansion. However, it is worth noting that in 3 out of
4 CD45RA2 Treg cultures there was more suppressive activity in
RAPA+ATRA cultures than in the RAPA alone cultures,
suggesting that the addition of ATRA to RAPA may help preserve
Treg activity during ex vivo expansion. These data highlight the
inherent differences of suppressive activity among human Treg
subsets. Moreover, they show that as a single agent, ATRA may
exert a detrimental effect on expanded Treg function, but in some
individuals, ATRA can augment RAPA-mediated Treg suppres-
sive activity.
Examination of the Treg-specific demethylated region
(TSDR) predicts functional activity
FOXP3 expression alone does not always correlate with human
T suppressor activity and as shown in Fig 2 and our previous work
, in vitro suppressive assays do not distinguish between transient and
sustained Treg suppressive activity. Recently, an association
between FOXP3 epigenetic status and suppressive function has
been made in both murine and human Tregs [4,16]. We wished to
determine whether epigenetic status of FOXP3 within the
previously defined Treg-specific demethylated region (TSDR)
correlated with functional activity. Prior to initiating the in vitro
suppression assay shown in Figure 5, genomic DNA was harvested
from Tregs cultured for 15 days in the presence of RAPA, ATRA,
ATRA plus RAPA, or no supplements at all. The DNA was
subjected to bisulfate conversion and epigenetic analysis to
determine the percentage of methylated versus demethylated
CpG residues within the TSDR locus (Fig 6). We saw a significant
correlation between the degree of suppression (Fig 5D–E) and the
percentage of demethylated CpG residues (correlation coeffi-
cient = 0.535, p = .03), supporting the use of this assay as a rapid
means to determine the suppressive potential of expanded Treg
populations.
Discussion
Several animal models have demonstrated the enormous
therapeutic potential of Tregs, but only recently have Tregs been
used to treat human disease . A key challenge to the field is to
develop approaches to generate therapeutic numbers of human
Tregs that retain their functionality, trafficking patterns and
survival ability once reinfused into the host. We chose to
investigate whether the retinoic acid derivative ATRA could
promote the expansion of natural Tregs, largely based on its ability
to ameliorate autoimmune diseases in mice, including type 1
diabetes [55], experimental allergic encephalomyelitis [36] and
colitis [37]. Several groups have investigated how retinoic acid
affects the generation of adaptive or inducible (iTregs), especially
in the gut environment [14], in order to understand how ATRA
alters the progression of autoimmune disease. Interestingly, ATRA
appears to promote gut homing of CD4 T cells by inducing CCR9
and a4b7 expression. Gut DCs are the most adept at generating
ATRA in vivo, causing some to speculate that the ability of ATRA
to generate iTregs in the gut is key to maintaining the balance
between tolerance and immunity [25]. How ATRA generates
iTregs is not completely understood, but the effect appears TGF-
b-dependent. By modulating RORct, it was previously demon-
strated that this ATRA target also contributes to FOXP3
upregulation . While TGF-b is required to observe ATRA-
mediated effects on FOXP3 expression, it is not clear if in the
absence of TGF-b, ATRA enhances Treg functional activity. Our
data suggest that ATRA alone may have a deleterious effect on
Treg functional activity, but in combination with RAPA, ATRA
may promote the expansion of Tregs with durable activity in the
absence of exogenously added TGF-b.
Because of the difficulty in isolating a pure population of Tregs
and ability of ATRA to augment FOXP3 expression, some groups
have investigated whether effector T cells could be converted to
Tregs using ATRA and TGF-b as a means of generating large
numbers of therapeutic Tregs . The obvious advantage of this
approach is that it would greatly reduce the number of GMP
reagents required to purify the starting cell population and would
greatly simplify the Treg expansion process. Most studies
performed in mice report robust in vivo suppressive activity of
TGF-b-induced Tregs in the treatment of colitis [22] and EAE
[41]. This suppressive activity should be further enhanced by
culture in the presence of ATRA . However, it is not clear from
these studies how long these induced Tregs needed to maintain
their suppressive phenotype to alter the disease course. A possible
flaw in the TGF-b/ATRA-based expansion strategy outlined
above is that T cells have a remarkable ability to modulate their
function in response to the surrounding cytokine and costimula-
tory milieu. While this post thymic iTreg development helps the
immune system to tailor its effector mechanism to target bacteria,
viruses or worms, it can be subverted to serve as an immune
escape mechanism if a particular tumor or infectious agent can
skew an antigen-specific T cell response from an effector to a
regulatory phenotype. Thus, ATRA/TGF-b-cultured cells may
appear to be Tregs following ex vivo expansion, but it is unclear
whether they will retain suppressive activity following re-infusion.
For instance, in a GVHD model, iTregs failed to retain FOXP3
expression and suppressive activity following reinfusion into the
host [26]. These data are reminiscent of the finding that purified
central memory T cells, ex vivo expanded under conditions
designed to endow them with an effector memory phenotype at
the end of the culture period, reverted and functioned as central
memory cells when infused into their hosts [9]. This suggests that
T cells have a mechanism to ‘‘remember’’ their phenotype prior to
ex vivo expansion, cautioning against the use of iTregs for
indications requiring long-term immunosuppression.
A limited number of studies have asked whether these same
principles of iTreg generation are conserved in human T cells.
While one study noted that ATRA could induce FOXP3 in the
absence of exogenous TGF-b, it wasn’t clear whether the media
used to expand these Tregs was TGF-b-free . A subsequent study
Influence of ATRA on Natural Tregs
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showed that indeed TGF-b was required for FOXP3 induction,
but this process was limited to naı¨ve T cells . In this report, human
iTregs generated by culture of CD4+CD252 T cells in the
presence of ATRA and TGF-b had in vitro suppressive activity and
other phenotypic characteristics of Tregs. This group also
examined the effect of ATRA/TGF-b treatment on the expansion
of enriched natural Tregs. They found that ATRA/TGF-b did not
hinder natural Treg growth, resulted in higher, more persistent
levels of FOXP3 expression, and generated Tregs with superior
suppressive activity at the end of two weeks of culture. As a result,
this group advocated the use of ATRA to expand natural as well as
adaptive Tregs. We were able to largely replicate these findings
using natural Tregs but came to the opposite conclusion regarding
the utility of expanding natural Tregs in the presence of ATRA.
Prolonged ex vivo expansion revealed to us that the effects of ATRA
on natural Tregs was transient, and did not result in the generation
of a durable Treg population. Moreover, ATRA treatment did not
suppress cytokine production in co-cultured FOXP32 T cells
(Fig 4), nor did it lead to upregulation of membrane bound TGF-b
(Fig 4), suggesting that Tregs expanded in this manner were not
well equipped to promote infectious tolerance. Lastly, ATRA
treatment did not enrich for T cells with a demethylated TSDR,
which others have shown to be strongly correlated with long-term
maintenance of the Treg suppressive phenotype [28].
Our studies examining the effect of ATRA on human Tregs are
reminiscent of studies of the effect of TGF-b on Tregs , and in fact
these findings may be interrelated. In mice, TGF-b appears to
induce FOXP3 expression and a suppressive phenotype in effector
CD4 T cells. In contrast, when human CD4 T cells are treated
with TGF-b, FOXP3 is induced but limited suppressive activity is
detected . Our studies indicate that ATRA is able to potentiate the
ability of TGF-b treated human CD4 T cells to impersonate
human T regulatory cells but ATRA as a single agent is unable to
promote the generation of Tregs that are attractive for use in
Figure 5. ATRA and RAPA affect Treg subsets equally. CD4+ CD25high CD45RA+ (A.) or CD4+ CD25high CD45RA2 (B.) populations were sort
purified and expanded by anti-CD3 Ab-loaded K.64.86 aAPCs in the presence of 100 ng/ml of rapamycin, 10 nM ATRA or a combination of both. After
12–15 days of culture, FOXP3 expression was measured by flow cytometry. Data from 4 unique donors is displayed. C. Representative suppression
data from a single donor using a 1:4 Treg to Effector ratio. D and E. Compiled suppression data from 4 donors (the donor in C. is the closed triangle).
doi:10.1371/journal.pone.0015868.g005
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therapeutic applications. The interplay between TGF-b, ATRA,
DNA methylation and T cell suppression is unclear. In some
models, ATRA induces the activation of latent TGF-b [11], but it
is unknown whether a similar mechanisms occurs in T cells.
Moreover, ATRA can bind a whole family of retinoic acid
receptors that can lead to a wide array of outcomes, some of which
promote immunity while others promote tolerance [54]. Thus,
understanding how ATRA hinders expansion of natural Tregs
whereas the combination of ATRA and RAPA enhances the
expansion of natural Tregs remains an open question.
While our studies indicate that ATRA is unsuitable as a single
agent for expansion of human Tregs, a case can be made for the
combined use of RAPA and ATRA. ATRA did not interfere with
RAPA’s ability to promote infectious tolerance (Fig 4A–C) and
only modestly diminished LAP expression (Fig 4D). Importantly, 3
out of 4 CD45RA2 Treg cultures grown in the presence of ATRA
and RAPA had higher suppressive activity than those expanded in
RAPA alone, suggesting that in the absence of TGF-b, ATRA
may potentiate RAPA’s effect on Treg stability and function.
Moreover, the use of ATRA during the ex vivo expansion of Tregs
destined to treat autoimmune diseases of the gut may be
particularly attractive, since ATRA upregulates expression of
CCR9 and other factors that promote migration into the gut .
Importantly, the use of RAPA and ATRA in Treg culture
increased the percentage of Tregs with demethylated FOXP3
alleles (Fig 6) suggesting that these Tregs are more likely to remain
as Tregs once re-infused in the patient and provide long lasting
and effective control of autoimmune disease.
Materials and Methods
Cell Isolation and Purification
Mononuclear cell enriched apheresis products were obtained by
leukapheresis of healthy volunteer donors by the University of
Pennsylvania Human Immunology Core. All specimens were
collected under a University Institutional Review Board-approved
protocol, and informed written consent was obtained from each
donor. CD4+ T cells were purified from the apheresis product
using RosetteSep human CD4+ T cell enrichment cocktail
(Stemcell Technologies, Vancouver, Canada). CD127dim,
CD25high T regulatory cells were sorted using a MoFlo high-
speed cell sorter (DakoCytomation). Where indicated, CD127dim,
CD25high, CD45RA+ and CD127dim, CD25high, CD45RA2
populations of Tregs were also sorted.
Stimulation and Expansion of Human T Cells
K.64.86, the K562-based artificial antigen presenting cell line
expressing CD64 (to enable loading of anti-CD3 Abs) and CD86,
was previously described [42]. K64.86 aAPCs were washed and
resuspended in serum-free culture medium (X-VIVO 15 medium,
LONZA, Walkersville, MD) 24 hours prior to antibody loading.
After 100Gy of irradiation, washing, and addition of 1 mg/ml anti-
CD3 Ab, the aAPCs were rotated at 4uC for 30 min, after which
unbound antibody was removed by washing three times. The Ab-
loaded K64.86 cells were resuspended in serum-free culture
medium at a density 16106 cells/ml, and combined with human T
cells (also in serum-free medium) at a final ratio of 1 K64.86 cell: 2
CD4 cells. Where indicated, rapamycin (Calbiochem, San Diego,
CA) was added on day 0 to a final concentration of 100 ng/ml.
All-trans-retinoic acid (Sigma-Aldrich, St. Louis, MO) (10 nM for
serum-free conditions and 10 mM for serum-containing conditions)
was added on day 0. Where indicated, human AB serum (Valley
Biomedical, Winchester, Virginia) was added to a final concen-
tration of 10% after 24 hrs of culture, while on day 2 of culture,
human IL-2 (Chiron Therapeutics, Emeryville, CA) was added to
a final concentration of 300 IU/ml. Cultures were monitored for
cell volume and cell density using a Coulter Multisizer 3 (Beckman
Coulter, Fullerton, CA) on days 5, 8, 12 and 15 of culture.
Following counting, the cell concentration was adjusted to 36105
T cells/ml by adding fresh medium supplemented with 300U/ml
IL-2 in the presence of ATRA and/or rapamycin, where
indicated.
In Vitro Suppression Assay
The suppression assay was performed as previously described .
Briefly, various ratios of expanded Tregs and CFSE2 labeled
autologous PBMCs were mixed with anti-CD3 Ab-coated beads
(Invitrogen Dynal AS, Oslo, Norway) using 1 bead per cell in
100 ml of media in round bottom 96 well plates (Corning
Incorporated, Corning, NY). Cultures were harvested 4 days later
and stained with APC-conjugated anti-CD8 antibodies (BD
Pharmingen, San Diego, CA). Data were acquired on a
FACSCalibur (BD Biosciences) flow cytometer using Cell Quest
Pro software and analyzed using FlowJo software (Tree Star Inc.,
Ashland, OR). For quantitative analysis of Treg suppression
capacity, the gates were placed on CD8+ CFSE+ cells. The
number of cells in each generation was determined using FlowJo
software. The percentage of undivided (PU) cells was calculated as
the percentage of cells in generation 0 at the end of the assay:
PU = N (0)/(N (0)+N (1)+…+N (m))6100. Fold expansion (FE) was
calculated as the number of offspring cells at the end of the assay
divided by the number of cells at the beginning of the assay:
FE = (N (1)+N (2)+…+N (m))/N estimated (0), where N estimated
(0) = N (0)+N (1)/2+N (2)/4+…+N (m21)/2m21.
Antibodies, Surface and Intracellular Staining
Anti-CD4-APC (555349), anti-CD8-APC (555369), anti-CD25-
PE (555432), anti-CD27-PE (555441), anti-CD62L-APC (559
772), anti-CD64-FITC (555527), anti-CD127-PE (557938), were
Figure 6. Status of the Treg-specific demethylated region
(TSDR) predicts functional activity. Prior to setting up the
suppression assays displayed in Fig 5, 1 million expanded T cells were
harvested, genomic DNA was prepared, and methylation status of TSDR
was determined as described in the Material and Methods. The
percentage of demethlyated CpG residues from two donors is
displayed. R, A, and RA refers to Tregs expanded in RAPA, ATRA or
RAPA and ATRA respectively.
doi:10.1371/journal.pone.0015868.g006
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obtained from BD Biosciences; anti-FOXP3-AlexaFluor 488 and
anti-FOXP3-Pacific Blue antibodies were purchased from Biole-
gend (San Diego, CA), anti-LAP-PE antibodies (FAB2463P) were
purchased from R&D Systems (Minneapolis, MN). Intracellular
FOXP3 staining was performed using the FOXP3 Fix/Perm
Buffer set (Biolegend) according to the manufacturer’s recommen-
dations. The intracellular cytokine assay was performed as
previously described [47].
DNA isolation and methylation analysis
Following in vitro T cell expansion, genomic DNA from 500,000
T cells was isolated using the DNeasy Kit (Qiagen, Germantown,
MD) per the manufacturer’s recommendations. Quantification of
the degree of methylation at the FOXP3-TSDR locus was
conducted by real-time PCR method and performed by Epiontis
(Berlin, Germany) as previously described [49].
Statistical Analysis
Statistical analysis was performed using the indicate test via
SigmaPlot v.11 software. P values equal to or less than 0.05 were
considered significant.
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